FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386208799> ?p ?o ?g. }

• W4386208799 endingPage "188" @default.
• W4386208799 startingPage "1" @default.
• W4386208799 abstract "Ovarian cancer affects the cells of the ovaries, and epithelial cancer is the most common type of malignant ovarian cancer. The homologous recombination repair pathway enables error-free repair of DNA double-strand breaks. Damage of key genes associated with this pathway leads to homologous recombination deficiency (HRD), which results in unrepaired DNA and can lead to cancer. Tumours with HRD are believed to be sensitive to treatment with poly-adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors, such as niraparib. We conducted a health technology assessment to evaluate the clinical utility and cost-effectiveness of HRD testing to inform patient decisions about the use of niraparib maintenance therapy for patients with high-grade serous or endometrioid epithelial ovarian cancer. We also evaluated the efficacy and safety of niraparib maintenance therapy in patients with HRD or homologous recombination proficiency (HRP), the cost-effectiveness of HRD testing, the budget impact of publicly funding HRD testing, and patient preferences and values.We performed a systematic literature search of the clinical evidence. We assessed the risk of bias of each included study using the Cochrane risk-of-bias tool for randomized trials version 2, and the quality of the body of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We performed a systematic economic literature search and conducted a cost-utility analysis with a 5-year time horizon from a public payer perspective. We also analyzed the budget impact of publicly funding HRD testing in people with ovarian cancer in Ontario. We performed a literature search for quantitative evidence of patient and provider preferences with respect to HRD testing and maintenance therapy with PARP inhibitors. To contextualize the potential value of HRD testing, we spoke with people with ovarian cancer.The clinical evidence review included two studies in high-grade epithelial ovarian cancer (one in patients with newly diagnosed advanced cases and one in patients with recurrent cancer). The studies evaluated niraparib maintenance therapy compared with no maintenance therapy and used HRD testing to group patients according to HRD status. Compared to placebo, niraparib maintenance therapy improved progression-free survival in patients with newly diagnosed and recurrent ovarian cancer, and in tumours with HRD or HRP (GRADE: High), but the studies did not compare the results between the HRD and HRP groups. The frequency of adverse events was higher in the niraparib group. We identified no studies that evaluated the clinical utility of HRD testing.We conducted a primary economic evaluation to evaluate the cost-effectiveness of HRD testing for people with newly diagnosed ovarian cancer in an Ontario setting. Our analysis used a 5-year time horizon. HRD testing (for all eligible people or only for people with BRCA wild type) resulted in a lower proportion of patients receiving niraparib maintenance therapy, leading to lower costs and fewer quality-adjusted life-years (QALYs). The average total cost per patient was $131,375 for no HRD testing, $126,867 for HRD testing only in people with BRCA wild type, and $127,746 for HRD testing in all eligible people. The average total QALYs per patient were 2.087 for no HRD testing, 1.971 for HRD testing only in people with BRCA wild type, and 1.971 for HRD testing in all eligible people. Our budget impact analysis suggested that assuming a high uptake rate, publicly funding HRD testing for people with newly diagnosed ovarian cancer would lead to a total saving of $9.00 million (if HRD testing were funded for all) to $12.67 million (if HRD testing were funded for people with BRCA wild type) over the next 5 years. Publicly funding HRD testing for people with recurrent cancer would lead to a total saving of $16.31 million (if HRD testing were funded for all) to $21.67 million (if HRD testing were funded for people with BRCA wild type) over the next 5 years.We identified no studies that evaluated quantitative preferences for HRD testing. Based on two studies that evaluated patients and oncologists' preferences for maintenance therapy with a PARP inhibitor in the recurrent setting, a decrease in moderate to severe adverse events was more important for patients than an improvement in progression-free survival; however, improvement in progression-free survival was more important for oncologists. Both patients and oncologists accepted some trade-offs between efficacy and safety. The people with ovarian cancer we spoke with demonstrated a shared value for access to information, prevention of cancer recurrence, and overall survival with minimal adverse effects. This was consistent with findings from another survey in patients with ovarian cancer and at least one episode of recurrence, which suggest that patients prioritize treatment benefit over some treatment adverse events in the context of niraparib maintenance therapy. Interviewees also emphasized the importance of the patient-doctor partnership, access to local health care services, and patient education.In patients with newly diagnosed (advanced) or recurrent high-grade serous or endometrioid ovarian cancer, niraparib maintenance therapy improved progression-free survival compared with no maintenance therapy in tumours with HRD or HRP (GRADE: High). Because we identified no studies on the clinical utility of HRD testing, we cannot comment on how it would affect patient decisions and clinical outcomes.Over a 5-year time horizon, HRD testing for people with BRCA wild type could save $4,509 per person and lead to a loss of 0.116 QALY. The findings of our economic analyses are dependent on assumptions about the use of niraparib following HRD testing. We estimate that publicly funding HRD testing would lead to a total saving of $9 million to $12.67 million for newly diagnosed cancer, and a total saving of $16.31 million to $21.67 million for recurrent cancer over 5 years, assuming the use of niraparib maintenance therapy would be reduced following HRD testing.Patients prioritized decreasing the risk of moderate to severe adverse events of maintenance therapy with PARP inhibitors over improving progression-free survival, and oncologists prioritized improving progression-free survival over decreasing the risk of moderate to severe adverse events. However, both patients and oncologists were open to accepting certain trade-offs between treatment efficacy and toxicity. The people we interviewed, who had lived experience with ovarian cancer and genetic testing, valued the potential clinical benefits of HRD testing for themselves and their family members. They emphasized patient education as an important consideration for public funding in Ontario." @default.
• W4386208799 created "2023-08-29" @default.
• W4386208799 date "2023-01-01" @default.
• W4386208799 modified "2023-09-30" @default.
• W4386208799 title "Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment." @default.
• W4386208799 cites W1964206180 @default.
• W4386208799 cites W1982967337 @default.
• W4386208799 cites W2024297717 @default.
• W4386208799 cites W2025741254 @default.
• W4386208799 cites W2025766222 @default.
• W4386208799 cites W2047677041 @default.
• W4386208799 cites W2100419317 @default.
• W4386208799 cites W2106010518 @default.
• W4386208799 cites W2109772731 @default.
• W4386208799 cites W2121828618 @default.
• W4386208799 cites W2134291881 @default.
• W4386208799 cites W2143025931 @default.
• W4386208799 cites W2180006003 @default.
• W4386208799 cites W2295085830 @default.
• W4386208799 cites W2299177375 @default.
• W4386208799 cites W2528228811 @default.
• W4386208799 cites W2594404528 @default.
• W4386208799 cites W2625869079 @default.
• W4386208799 cites W2754327139 @default.
• W4386208799 cites W2771690491 @default.
• W4386208799 cites W2788656587 @default.
• W4386208799 cites W2804007674 @default.
• W4386208799 cites W2806580171 @default.
• W4386208799 cites W2812198121 @default.
• W4386208799 cites W2884001607 @default.
• W4386208799 cites W2895598060 @default.
• W4386208799 cites W2896250649 @default.
• W4386208799 cites W2897430921 @default.
• W4386208799 cites W2908639608 @default.
• W4386208799 cites W2917476978 @default.
• W4386208799 cites W2925017121 @default.
• W4386208799 cites W2935541805 @default.
• W4386208799 cites W2948947061 @default.
• W4386208799 cites W2970684805 @default.
• W4386208799 cites W2975141952 @default.
• W4386208799 cites W2976139792 @default.
• W4386208799 cites W2994977341 @default.
• W4386208799 cites W3001210504 @default.
• W4386208799 cites W3001632091 @default.
• W4386208799 cites W3012991619 @default.
• W4386208799 cites W3043469226 @default.
• W4386208799 cites W3047403276 @default.
• W4386208799 cites W3048967410 @default.
• W4386208799 cites W3080595870 @default.
• W4386208799 cites W3080985895 @default.
• W4386208799 cites W3089254712 @default.
• W4386208799 cites W3089768241 @default.
• W4386208799 cites W3091954588 @default.
• W4386208799 cites W3093338574 @default.
• W4386208799 cites W3095003868 @default.
• W4386208799 cites W3111983537 @default.
• W4386208799 cites W3113307403 @default.
• W4386208799 cites W3117058342 @default.
• W4386208799 cites W3135164481 @default.
• W4386208799 cites W3135570724 @default.
• W4386208799 cites W3141256924 @default.
• W4386208799 cites W3166364901 @default.
• W4386208799 cites W3205483914 @default.
• W4386208799 cites W3215585343 @default.
• W4386208799 cites W3216295539 @default.
• W4386208799 cites W4200331559 @default.
• W4386208799 cites W4200478852 @default.
• W4386208799 cites W4205309211 @default.
• W4386208799 cites W4206896499 @default.
• W4386208799 cites W4220740241 @default.
• W4386208799 cites W4220932078 @default.
• W4386208799 cites W4221086822 @default.
• W4386208799 cites W4229450749 @default.
• W4386208799 cites W4281617860 @default.
• W4386208799 cites W4283020357 @default.
• W4386208799 cites W4285741861 @default.
• W4386208799 cites W4296640366 @default.
• W4386208799 cites W4308783150 @default.
• W4386208799 cites W4308834462 @default.
• W4386208799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37637244" @default.
• W4386208799 hasPublicationYear "2023" @default.
• W4386208799 type Work @default.
• W4386208799 citedByCount "0" @default.
• W4386208799 crossrefType "journal-article" @default.
• W4386208799 hasConcept C102744134 @default.
• W4386208799 hasConcept C104317684 @default.
• W4386208799 hasConcept C121608353 @default.
• W4386208799 hasConcept C126322002 @default.
• W4386208799 hasConcept C143998085 @default.
• W4386208799 hasConcept C150173356 @default.
• W4386208799 hasConcept C2780427987 @default.
• W4386208799 hasConcept C2992773878 @default.
• W4386208799 hasConcept C2993684365 @default.
• W4386208799 hasConcept C502942594 @default.
• W4386208799 hasConcept C54355233 @default.
• W4386208799 hasConcept C71924100 @default.
• W4386208799 hasConcept C86803240 @default.
• W4386208799 hasConceptScore W4386208799C102744134 @default.

• next